New drug duo tested in fight against aggressive blood cancer
NCT ID NCT04512534
Summary
This study is testing whether a combination of two drugs, sintilimab and chidamide, can help control a difficult-to-treat type of blood cancer called peripheral T-cell lymphoma in patients for whom prior treatments have stopped working. The trial will enroll up to 51 adults to see how well the combination works at stopping cancer growth and how safe it is. Participants will receive the drugs every three weeks for up to two years, or until the cancer progresses or side effects become too severe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Dongmei Ji
RECRUITINGShanghai, Shanghai Municipality, 021, China
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.